In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological…
In connection with the implementation of the project titled “Design and development of an innovative solution – a drug from the group of GLP-1 receptor…
Markus’ previous experience in Medicines for Europe spans the range of priority topics for our sector, including the EU pharmaceutical legislation, Critical Medicines Act, the…
The letter, signed by CEOs and senior executives from across the European off-patent medicines sector, focuses on the need to: Accelerate the adoption of the…
In connection with the implementation of the project titled “Development and introduction to the medical market of the first non-antibiotic product in the treatment of…
Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.
By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.